Close

Aravive Inc. (ARAV) PT Raised to $28 at Wedbush

Go back to Aravive Inc. (ARAV) PT Raised to $28 at Wedbush

Aravive Inc. (ARAV) PT Raised to $31 at H.C. Wainwright

November 20, 2019 12:14 PM EST

H.C. Wainwright analyst Joseph Pantginis raised the price target on Aravive Inc. (NASDAQ: ARAV) to $31.00 (from $18.00) while maintaining a Buy rating.

The analyst commented, "This morning, Aravive announced new positive data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of... More